Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Diabetes Care · 2026
DOI: 10.2337/dc25-2008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Jeffrey S Gonzalez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Blood Glucose, Medication Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS GRADE participants (type 2 diabetes duration <10 years, HbA1c 6.8%–8.5%, on metformin alone) were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Adherence was measured semiannually for 3 years using a validated three-item scale (0–100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes. RESULTS Overall mean ± SD adherence (average of participant-level mean ± SD) was high over 3 years of follow-up at 88.7 ± 10.01, on a scale of 0–100, and decreased slightly by 3 years relative to baseline (−2.0 ± 14.7; P < 0.0001). No intergroup differences were observed until 3 years, when adherence was 5% and 3% higher for the glimepiride and sitagliptin groups, respectively, than for liraglutide (both P < 0.05). Over follow-up and across groups, a 10-point decrease in adherence was associated with 15% and 19% increased risk of reaching primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes (both P < 0.0001). Lower adherence was somewhat more predictive of the secondary outcome for those assigned to glargine or liraglutide, compared with glimepiride or sitagliptin (each P < 0.05). No other comparisons were significant. CONCLUSIONS Medication adherence was consistently high in GRADE. Observed treatment group differences were small and of unclear clinical significance. Overall, lower adherence robustly predicted worsening glycemic control, highlighting the importance of ongoing assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY.
- Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
- New York Regional Center for Diabetes Translation Research, Albert Einstein College of Medicine, Bronx, NY.
- Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
- Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA.
ORCID-Profile: Jeffrey S Gonzalez, Nicole M Butera, Heidi Krause-Steinrauf, Michaela R Gramzinski, Deborah J Wexler, Claire J Hoogendoorn, Caroline Presley, Andrea L Cherrington
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- NIDDK NIH HHS
- American Diabetes Association
- NIGMS NIH HHS
- NIA NIH HHS
- CDC HHS
Zitieren
APA
Gonzalez, J. S., Wen, H., Butera, N. M., Uschner, D., Krause-Steinrauf, H., Gramzinski, M. R., Wexler, D. J., Petrovitch, H., Hoogendoorn, C. J., Crespo-Ramos, G., Presley, C., Fattaleh, B., Lagari, V., Walker, E. A., Cherrington, A. L., & GRADE Research Group* (2026). Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. https://doi.org/10.2337/dc25-2008
Vancouver
Gonzalez JS, Wen H, Butera NM, Uschner D, Krause-Steinrauf H, Gramzinski MR, et al. Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026. doi:10.2337/dc25-2008
BibTeX
@article{Gonzalez2026,
author = {Gonzalez, Jeffrey S and Wen, Hui and Butera, Nicole M and Uschner, Diane and Krause-Steinrauf, Heidi and Gramzinski, Michaela R and Wexler, Deborah J and Petrovitch, Helen and Hoogendoorn, Claire J and Crespo-Ramos, Gladys and Presley, Caroline and Fattaleh, Basma and Lagari, Violet and Walker, Elizabeth A and Cherrington, Andrea L and GRADE Research Group*, GRADE Research Group*},
title = {Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-2008}
}
EUVIMED